Overview

A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Status:
Withdrawn

Trial end date:
2015-09-01

Target enrollment:

Participant gender:

Summary

This trial is conducted in Europe. The aim of the trial is to investigate the mechanism of action of NNC0109-0012 (anti-IL-20 mAb) through synovial biopsies in subjects with rheumatoid arthritis (RA) and an inadequate response to Methotrexate.

Phase:

Phase 2

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Adalimumab
Antibodies, Monoclonal
Methotrexate